4.7 Article

Molecular modeling study of tectoquinone and acteoside fromTectona grandislinn: a new SARS-CoV-2 main protease inhibitor against COVID-19

期刊

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
卷 40, 期 4, 页码 1764-1775

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2020.1832580

关键词

Tectoquinone; Acteoside; SARS-CoV-2; Mpro inhibitor; COVID-19; molecular modeling

向作者/读者索取更多资源

COVID-19, caused by SARS-CoV-2, is a highly contagious disease with no specific antiviral drugs available. This study examines the potential of Tectoquinone and Acteoside, phytocompounds, in inhibiting the viral protease of SARS-CoV-2. Molecular docking and dynamics simulations reveal their stability and binding energies, supporting their use as potential therapeutic agents.
Coronavirus disease 2019 (COVID-19), a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has drastically changed the lifestyle of people around the globe. Due to the lack of specific and effective antiviral drugs, transmission of the disease increases exponentially and makes it more serious and harder to control. Drugs that were assumed to be effective against COVID-19 have failed in various stages of clinical trials and this made the scientific community more disappointed. But, the race of researchers for developing new and effective antiviral to stop the disease progression still continues and our work is one among them. This study is an attempt to analyze the action of Tectoquinone and Acteoside; an important phytocompound, on SARS-CoV2 viral protease via in silico approach. The compounds were selected on the basis of their molecular docking values and they were subjected to molecular dynamics simulations about 50 ns to determine the stability and the thermodynamic feasibility between the target and the ligands. Binding energies like hydrogen bonding, hydrophobic and electrostatic interactions of the complexes were determined after MD simulations. The Pharmacokinetics and drug likeness evaluation of the compounds provide a strong evidence for the use of these compounds in developing drugs for clinical trials. Thus, the current study reveals the potential phytoconstituents present inTectona grandisLinn to inhibit COVID-19 viral protease and thereby act as a lead therapeutic agent. Communicated by Ramaswamy H. Sarma

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据